Menu
Assessment of new technologies and approaches in cancer screening
Summary
We will explore the potential for extending the application of the methodology developed in task 4.4.4 for assessing AI technologies and novel approaches in cancer screening tests across Europe. The aim is to apply the MAS-AI methodology adopted to the European context in 2-3 clinical use cases from participating countries. The inclusion criteria for the use cases is that they are built on or utilize state-of-the-art AI technology as a component in the national cancer screening programs in participating countries. By applying the model on specific European use cases, the aim is to assess the feasibility, acceptability and comprehensibility of the model in different countries across Europe and to validate the transferability of the model in the context of European cancer screening.
This task will be led by RSYD, Denmark, co-led by CPO, Italy and EMC, the Netherlands
Subscribe to our newsletter to get news and updates.
Subscribe to our newsletter to get news and updates.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.
The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959
